Go Pro
NASDAQ:MGX

Metagenomi Q3 2025 Earnings Report

Metagenomi logo
$1.15 0.00 (0.00%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.15 0.00 (-0.09%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Metagenomi EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Metagenomi Revenue Results

Actual Revenue
$8.66 million
Expected Revenue
$7.82 million
Beat/Miss
Beat by +$836.00 thousand
YoY Revenue Growth
N/A

Metagenomi Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Metagenomi's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Metagenomi Earnings Headlines

Metagenomi updates hemophilia A gene editing program
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Metagenomi Therapeutics Inc MGX
See More Metagenomi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email.

About Metagenomi

Metagenomi (NASDAQ:MGX) is a biotechnology company developing genetic medicines using genome-editing technologies discovered through metagenomic research. The company searches genetic material from diverse microorganisms to identify naturally occurring editing systems and combines these discoveries with machine-learning tools to develop potential therapies.

Its research platform is designed to support the development of genome-editing medicines for a range of diseases, including programs intended to make precise changes to DNA in human cells. Metagenomi’s product candidates and discovery efforts have focused on both in vivo and ex vivo applications, although the status and scope of individual programs may change as the company advances its research pipeline.

Founded in 2018, Metagenomi is headquartered in Emeryville, California, and has pursued collaborations and strategic relationships with larger life-sciences companies to support the development and potential commercialization of its technologies. The company was co-founded by Brian C. Thomas, Ph.D., who has served as its chief executive officer. Metagenomi began trading publicly on the Nasdaq under the symbol MGX in 2024.

View Metagenomi Profile